N-(4-TERT-BUTYLBENZYL)-3-(1-FLUOROETHYL)-1-METHYL-1H-PYRAZOLE-5-CARBOXAMIDE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	SNXUNMVRFUCKDO-UHFFFAOYSA-N
Smiles	CC(F)c1cc(C(=O)NCc2ccc(cc2)C(C)(C)C)n(C)n1
InChI	InChI=1S/C18H24FN3O/c1-12(19)15-10-16(22(5)21-15)17(23)20-11-13-6-8-14(9-7-13)18(2,3)4/h6-10,12H,11H2,1-5H3,(H,20,23)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C18H24FN3O
Molecular Weight	317.4
AlogP	4.0
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	5.0
Polar Surface Area	46.92
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	23.0

Assay Description	Organism	Bioactivity
Acaricidal activity against Tetranychus urticae (two-spotted spider mite) assessed as fertility inhibition at 0.16 g/L measured after 6 days	Tetranychus urticae	94.0 %
Acaricidal activity against Tetranychus urticae (two-spotted spider mite) assessed as fertility inhibition at 0.16 g/L measured after 4 days	Tetranychus urticae	91.0 %
Acaricidal activity against Tetranychus urticae (two-spotted spider mite) assessed as fertility inhibition at 0.16 g/L measured after 24 hr	Tetranychus urticae	68.0 %
Acaricidal activity against Tetranychus urticae (two-spotted spider mite) assessed as fertility inhibition at 5 g/L measured after 4 days	Tetranychus urticae	96.0 %
Acaricidal activity against Tetranychus urticae (two-spotted spider mite) assessed as fertility inhibition at 5 g/L measured after 6 days	Tetranychus urticae	100.0 %
Acaricidal activity against Tetranychus urticae (two-spotted spider mite) assessed as fertility inhibition at 5 g/L measured after 24 hr	Tetranychus urticae	100.0 %
Acaricidal activity against Tetranychus urticae (two-spotted spider mite) assessed as mortality at 0.16 g/L measured after 6 days	Tetranychus urticae	10.0 %
Acaricidal activity against Tetranychus urticae (two-spotted spider mite) assessed as mortality at 0.16 g/L measured after 4 days	Tetranychus urticae	10.0 %
Acaricidal activity against Tetranychus urticae (two-spotted spider mite) assessed as mortality at 0.16 g/L measured after 24 hr	Tetranychus urticae	16.0 %
Acaricidal activity against Tetranychus urticae (two-spotted spider mite) assessed as mortality at 5 g/L measured after 4 days	Tetranychus urticae	70.0 %
Acaricidal activity against Tetranychus urticae (two-spotted spider mite) assessed as mortality at 5 g/L measured after 6 days	Tetranychus urticae	80.0 %
Acaricidal activity against Tetranychus urticae (two-spotted spider mite) assessed as mortality at 5 g/L measured after 24 hr	Tetranychus urticae	70.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2270137
PubChem	25137367

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).